Aino Health has received around SEK 29.6 million in cash through an oversubscribed preferential rights issue and a supplementary issue directed at Swedbank Robur Fonder.
An extraordinary general meeting of Aino Health AB (publ) on 14 August 2018 resolved to approve the Board’s proposal for a new issue of units with preferential rights for shareholders, and resolved to authorize the Company’s management team to approve further issues within the limits of the Articles of Association. The new issue encompassed at most 7,230,360 units, each consisting of one share and one subscription option, at a price of SEK 3.40.
Excluding remuneration to guarantors choosing to offset against newly issued shares, a total of 9,700,204 units, of which 5,427,728 with preferential rights and 4,272,476 without preferential rights, were subscribed. The full number in the issue, 7,230,360 units, will therefore be allotted. The Board has also resolved to use its authorization to perform a supplementary directed issue, as already communicated in the memorandum on the issue, whereby the Company will be emitting another 1,470,588 units (SEK 5 million) at the same price per share as in the preferential issue. The subscriber in the directed issue is Swedbank Robur Fonder, which following the imminent registration will own around 9.2% of the Company. In total, Aino Health will receive a cash settlement of SEK 29.6 million before costs for the issues. The offsets resolved upon by the extraordinary general meeting of 14 August 2018 will be handled separately, in accordance with previous general meeting resolutions, and will mean that another approximately 1,341,765 shares and subscription options will be issued, with a separate series of subscription options, SO2 (on identical terms as SO1). As a preliminary estimate, 468,824 units will be issued as remuneration to guarantors that have chosen the option of offsetting remuneration against newly issued shares.
After the registration of all the aforementioned newly issued units, there will be a total of 15,934,307 shares in the Company and a total of 10,511,537 subscription options in series SO1 and SO2 combined. The share capital will increase by SEK 26,278,842.50 to SEK 39,835,767.5. Minor adjustments in the numbers of shares and sums herein mentioned may occur in connection with the final registration at the Swedish Companies Registration Office.
Subscription of units, with and without preferential rights, occurred during the period 10–26 September 2018. Subscribers with subsidiary rights have been granted full allotment. The allotment of the units subscribed without preferential rights was performed in accordance with the principles stated in the memorandum on the issue. Notice on allotment of units subscribed without preferential rights will shortly be sent to those that were allotted units. Units are to be paid in accordance with the instructions on the contract note.
G&W Fondkommission has acted as financial advisor and Advokatfirman Lindahl KB has been the legal advisor in connection with the issue.
As soon as the increase in share capital has been registered with the Swedish Companies Registration Office, paid subscribed units (PSU) in the preferential issue will be transformed into new shares and subscription options. Until then, trade in PSUs will be performed on Nasdaq First North. The commencement of trading of new shares and subscription options in series SO1 on Nasdaq First North will be announced in a separate press release.
Aino Health’s CEO Jyrki Eklund says: ”We are immensely proud of and pleased with the attention that Aino Health has garnered. We would like to welcome our new shareholders along on the exciting journey we have ahead of us. In particular, we want to welcome Swedbank Robur Fonder as an institutional shareholder. The capital received provides us with the ability to intensify our market activities, further develop our organisation and strengthen our offerings.”
The information contained herein is such as shall be made public by Aino Health AB (publ), in accordance with the EU Market Abuse Regulation. This information was made public, through the agency of Jyrki Eklund, CEO and President of Aino Health AB, at 08.30 AM CEST on October 1 2018.
For more information:
Jyrki Eklund, CEO of Aino Health, Phone: +358 40 042 4221
About Aino Health (publ)
Aino Health is the leading supplier of Software as a Service solutions in Corporate Health Management. The company’s complete system of SaaS platforms and services reduces sick leave, lowers related costs and delivers long term prosperity, increased productivity and employee engagement by adopting health, wellbeing and safety as an everyday activity. For more information visit ainohealth.com.
Aino Health AB (publ) is listed at Nasdaq First North Stockholm (Ticker: AINO). Erik Penser Bank AB, +46 8 463 83 00, is the Certified Adviser to the company.